"Erlotinib in the treatment of advanced squamous cell NSCLC"@en . "2"^^ . "RIV/26475821:_____/13:#0000174" . "RIV/26475821:_____/13:#0000174!RIV14-MZ0-26475821" . . "SK - Slovensk\u00E1 republika" . "Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001).The most common adverse effects were rash and diarrhoea. In conclusion ertlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC."@en . "6" . "Erlotinib in the treatment of advanced squamous cell NSCLC"@en . "Neoplasma" . . . . . "10"^^ . . . . . "Min\u00E1rik, Marek" . . "60" . . . . . "7"^^ . . . . "Erlotinib in the treatment of advanced squamous cell NSCLC" . "10.4149/neo_2013_086" . "Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001).The most common adverse effects were rash and diarrhoea. In conclusion ertlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC." . . "I, P(NR9087), V" . "squamous cell, NSCLC, erlotinib, targeted treatment, EGFR-TKI"@en . "73177" . "Bene\u0161ov\u00E1, Lucie" . . . "Erlotinib in the treatment of advanced squamous cell NSCLC" . "http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=3513&category_id=102&option=com_virtuemart" . "[E7447A7028F5]" . "0028-2685" . .